Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 1.00 |
| ▸ | CRHR2 | Q13324 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | IDH1 | O75874 | 1/20 | 0.66 |
| ▸ | NAT1 | P18440 | 3/20 | 0.64 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309015 | 1.00 | CRHBP (1.00) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL13846818 | 0.86 | IGF1R (1.00) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL1250598 | 0.86 | IGF1R (1.00) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL1250596 | 0.86 | IGF1R (1.00) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL6413727 | 0.84 | IGF1R (0.76) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL6413731 | 0.84 | IGF1R (0.76) | CRHBPCRHR2IGF1RMEN1KMT2A | |
| SCHEMBL15091291 | 0.83 | CRHBP (0.71) | CRHBPCRHR2GSK3BIDH1NAT1 | |
| SCHEMBL1250835 | 0.83 | CRHBP (0.71) | CRHBPCRHR2GSK3BIDH1NAT1 | |
| SCHEMBL1250831 | 0.83 | CRHBP (0.71) | CRHBPCRHR2GSK3BIDH1NAT1 | |
| SCHEMBL15097009 | 0.81 | CRHBP (0.67) | CRHBPCRHR2IGF1RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-8569346-B1 | Thiazoline ring compounds as botulinum antagonists | BIOMADISON, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-4207103-A | EMULSION CONTAINS ONE ELECTRON ACCEPTING COMPOUND AS DESENSITIZER | EASTMAN KODAK COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4152152-A | Additives for contrast control in organic photoconductor compositions and elements | EASTMAN KODAK COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CRHBP 3022/4885CRHR2 3001/4885IGF1R 2493/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CRHBP 3022/4885CRHR2 3001/4885IGF1R 2493/4885 |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | CRHBP 732/4885CRHR2 2408/4885IGF1R 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.